Hernexeos (Zongertinib)

Zongertinib is a medicine for a type of advanced lung cancer that has a change in the HER2 gene. It is taken as a pill by mouth. It works by blocking the HER2 protein that tells the cancer cells to grow.

Brand names:Hernexeos
Medication

What people taking Hernexeos (Zongertinib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Hernexeos (Zongertinib) for Non-Small Cell Lung Cancer?

NameHow it went

About Hernexeos (Zongertinib)

What It's For

Zongertinib, sold as Hernexeos, is a targeted cancer pill for adults with non-small cell lung cancer (NSCLC), the most common kind of lung cancer. It is approved for the non-squamous type of NSCLC when the cancer cannot be removed with surgery or has spread to other parts of the body, and only when the tumor carries a particular change, called an activating mutation, in the HER2 gene (human epidermal growth factor receptor 2, also known as ERBB2). These mutations are uncommon, found in roughly 1 to 5 percent of NSCLC, and are seen more often in women and in people who never smoked. Whether zongertinib fits depends on a test for the mutation itself, done with a test authorized by the US Food and Drug Administration (FDA) on a blood sample or on tumor tissue. If a blood test finds nothing, tumor tissue is tested. It can be used as a first treatment for advanced disease or after platinum chemotherapy. This is an accelerated approval. The FDA approved it because tumors shrank in a high share of people in its main study, before trials have shown whether it helps people live longer. Continued approval depends on a confirmatory trial. Other HER2-targeted options exist, including trastuzumab deruxtecan (an antibody that carries chemotherapy into cancer cells) and sevabertinib (Hyrnuo, another HER2-blocking pill).

How It Works

HER2 is a receptor on the surface of cells that relays growth signals into the cell. In some lung cancers, a mutation in the part of HER2 that switches it on, called the tyrosine kinase domain, leaves it stuck in the on position, so it keeps telling the cancer cells to grow and divide. Zongertinib is a kinase inhibitor: it blocks that switch from inside the cell, shutting down the signal the mutated HER2 sends. In laboratory studies this stopped the growth of lung cancer cells carrying these mutations. Because it acts on a specific mutation, it works only in tumors that have one, which is why testing comes first. It controls the cancer rather than curing it, and many cancers eventually find a way around the blockade.

Dosage & Administration

Zongertinib is a tablet taken by mouth once a day, with or without food, and is continued for as long as it keeps the cancer under control and side effects remain manageable. The dose depends on body weight: people under 90 kg (about 198 pounds) usually take 120 mg, two 60 mg tablets, and people at or above that weight take 180 mg, three tablets. Swallow the tablets whole with water; do not split, crush or chew them. If a dose is missed and fewer than 12 hours have passed, take it; if more than 12 hours have passed, skip it and take the next dose at the usual time. If you vomit after a dose, do not take an extra one; take the next dose at the usual time. If you take too much, call the care team or go to the nearest emergency room right away. The oncologist may pause treatment or lower the dose to 120 mg or 60 mg to manage side effects. Do not change the dose or stop on your own.

Side Effects

Diarrhea is the most common side effect, affecting about half of people, and it can become severe. Rash, tiredness, nausea, muscle and joint pain, and colds or other upper respiratory infections are also common. Tell the care team right away about new or worsening diarrhea. It is usually treated with anti-diarrhea medicine and, if it persists, a pause in treatment or a lower dose, and acting early helps keep it from causing dehydration. Three serious effects are monitored throughout treatment. Liver injury is common and can be severe. Blood tests check the liver before starting, every two weeks for the first 12 weeks and then about monthly. Call the care team right away for yellowing of the skin or the whites of the eyes, dark or tea-colored urine, pain in the upper right part of the belly, easier bleeding or bruising, or unusual tiredness with loss of appetite. The heart's pumping strength can weaken. It is measured before treatment and at intervals afterward, often with an echocardiogram (heart ultrasound). Report a pounding or racing heartbeat, new shortness of breath, dizziness or fainting, or swelling of the legs, ankles or feet right away. Lung inflammation, called pneumonitis, is uncommon but can be life-threatening. New or worsening cough, shortness of breath or fever needs prompt contact with the care team, because these symptoms can overlap with the lung cancer itself or an infection and need to be checked.

Interactions & Warnings

Some medicines change how zongertinib works. Strong enzyme-inducing drugs, such as the seizure medicine carbamazepine, can sharply lower zongertinib levels and make it less effective, so they are avoided where possible. Zongertinib in turn can raise levels of some other medicines, such as the cholesterol drug rosuvastatin, which may increase their side effects. Tell the oncologist and pharmacist about every prescription, over-the-counter medicine, vitamin and herbal supplement before starting or adding anything. Zongertinib can harm a developing baby. People who can become pregnant have a pregnancy test before starting, should use effective birth control during treatment and for 2 weeks after the last dose, and should tell the care team right away about a possible pregnancy. Breastfeeding is not recommended during treatment or for 2 weeks after the last dose. It may also reduce fertility in women and men, which is worth discussing before treatment if future children matter to you. It was not studied in people with significant heart disease, reduced heart pumping strength or a past history of lung inflammation not caused by infection, so those conditions call for a careful conversation before starting.

What to Expect

In the main study, about three in four people whose cancer had a qualifying HER2 mutation saw their tumors shrink substantially, both among those starting their first treatment and among those who had already had chemotherapy. In the first-treatment group, nearly half of these responses lasted a year or longer. Responses were less common and shorter in people whose cancer had already progressed after a HER2-targeted antibody-drug conjugate. A small number of people with cancer in the brain also saw those tumors shrink. These results come from a study without a comparison group, so how zongertinib compares with other treatments is not yet known. Life on zongertinib means frequent blood tests at first, regular heart checks and periodic scans to see whether the cancer is responding. Many people take it for months or longer. Treatment usually continues until scans show the cancer growing again or side effects become too difficult, at which point the oncologist discusses next options.

Questions to Ask Your Doctor

  1. 1.Which test confirmed my HER2 mutation, and does my result clearly qualify for zongertinib?
  2. 2.Why do you recommend zongertinib over trastuzumab deruxtecan, sevabertinib or chemotherapy for me, and what would come next if it stops working?
  3. 3.How should I manage diarrhea at home, and at what point should I call you?
  4. 4.How often will I need liver blood tests, heart checks and scans, and how will we know it is working?
  5. 5.Do any of my current medicines or supplements interact with zongertinib, and what should I know about birth control or fertility?

Last reviewed • Oct 2026

Educational content, not medical advice.